• YAKHAK HOEJI
• /
• v.54 no.4
• /
• pp.309-315
• /
• 2010

The Positive List System was newly introduced in South Korea as of January 2007. This study aims to survey and compare perception of and attitudes toward the Positive List System in the process of new drug listing that health professionals and pharmaceutical companies have. 50 professionals and 52 companies answered the questionnaire regarding health policy environments, policy decision/enforcement process, policy effects and satisfaction related to introducing the Positive List System. SAS 9.1 was used for statistical analyses. The results showed that participants had the general sympathy with health policy environments for the introduction of the Positive List System into South Korea. However, the response rates of policy decision/enforcement process and effects were negative and these tendencies were more striking in pharmaceutical companies. As for policy satisfaction, participants marked positive responses more than negative ones. It is necessary to remedy and supplement problems with policy decision/enforcement policy and effects revealed in this study and to improve the Positive List System through gathering opinions among groups and organization concerned.

• YAKHAK HOEJI
• /
• v.55 no.4
• /
• pp.338-344
• /
• 2011

This study aimed to identify the changes in the list of drugs covered by national health insurance(NHI) after the introduction of positive list system (PLS) in Korea in December, 2006. Six-year (pre-policy:2004-2006, post-policy:2007-2009) lists of the NHI reimbursable drugs filed from Health Insurance Review and Assessment Service (HIRA) were analyzed. The total number of listed drugs as well as drug ingredients, and the average number of listed drugs per manufacturer decreased annually after the introduction of PLS. More than 8,000 drugs were delisted in the year 2007 right after the policy change. Prescription-only drugs occupied more than 85% of NHI listed drugs. The percentage of oral type of listed drugs has been increased to more than 60% after the policy change. Korean pharmaceutical manufacturers occupied more than 90% of listed drugs than multinational firms. The gap between Korean and foreign manufacturer in terms of the average number of newly listed drugs per manufacturer in each year has decreased two years after the PLS (Korean 7.7 vs. foreign 6.3 in 2009) as the price negotiation power of foreign firms has increased. The total number of listed drugs is expected to decrease in the future as the Korean government makes an effort to delist the unnecessary drugs that do not show cost-effectiveness.

• The monthly packaging world
• /
• s.158
• /
• pp.58-67
• /
• 2006

• The monthly packaging world
• /
• s.140
• /
• pp.148-168
• /
• 2004

• Journal of Preventive Medicine and Public Health
• /
• v.41 no.2
• /
• pp.69-73
• /
• 2008

To curb a rapid increase in expenditures for pharmaceuticals, the Korean government introduced a positive list system and a negotiation process for drug prices at the end of 2006. Economic evaluation of pharmaceuticals has begun to have a pivotal role in the listing and pricing of drugs for the Korean National Health Insurance. There are some points to discuss regarding the use of economic evaluation in the listing and pricing in the context of the Korean system. First, the listing and pricing processes have been fragmented, evoking complaints from pharmaceutical companies and delaying the access of new drugs to patients. Second, there is a concern that the positive list system may limit the range and availability of drugs for patients to choose for treatment. Third, the time schedule for de-listing of existing drugs may not be realistic. Fourth, it is not always easy to provide reliable evidence of cost-effectiveness due to a lack of materials. Fifth, there is no consensus on the range of the ICER (incremental cost-effectiveness ratio) acceptable to the Korean society. In conclusion, in the near future, it will be necessary to evaluate the achievements that the economic evaluation has provided to the Korean society.

• Kyungpook Mathematical Journal
• /
• v.63 no.3
• /
• pp.355-372
• /
• 2023

We make advances towards a structural characterisation of the signed graphs H for which the list switch H-colouring problem List-S-Hom(H) can be solved in polynomial time. We conjecture two different characterisations, the second refining the first, in the case that the graph H can be switched to a graph in which every negative edge is also positive. Using a recent proof of the first characterisations for reflexive signed graphs, by Bok et. al., we prove the second characterisation for reflexive signed graphs. We also provide several tools for reducing the problem to the bipartite case, and prove a full complexity dichotomy for a related problem.

• The monthly packaging world
• /
• s.207
• /
• pp.75-89
• /
• 2010

• The monthly packaging world
• /
• s.327
• /
• pp.72-77
• /
• 2020

• Journal of the Society of Cosmetic Scientists of Korea
• /
• v.28 no.3
• /
• pp.109-145
• /
• 2002

Council Directive 76/768/EEC forms the basis of the actual legislation of cosmetics in the European Union (EU). After a short introduction on the background and philosophy of this legislation, the key points will be discussed. In particular, attention will be given to the basic principles for safety and in this context the effects of the implementation of the 6th Amendment (Council Directive 93/35/EC) will be analysed. The major points for discussion will be: the safety requirements for cosmetics and the final responsibility for bringing these products on the EU market; the EU concept of safety of the finished product based on the safety of the individual ingredients; the existence of positive and negative lists of ingredients and the requirement for a European dossier for all finished products. Special attention will be given to the use of validated alternative methods and the consequences of the new proposal of a 7th Amendment. Finally, the safety evaluation as it is done by the SCCNFP (Scientific Committee on Cosmetics and Non-Food Products) in the case of an ingredient present on the positive lists and the evaluation done by a safety assessor in the case of a technical information file for a finished product, both will be discussed in detail.

• Journal of the Korean Mathematical Society
• /
• v.45 no.3
• /
• pp.621-630
• /
• 2008

In this paper, we provide a complete list of 177 equivalence classes of primitive even 2-regular quaternary positive definite quadratic forms and their discriminants. All of them have class number 1.